Filing Details

Accession Number:
0001140361-18-026543
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-05-31 16:13:38
Reporting Period:
2018-05-29
Accepted Time:
2018-05-31 16:13:38
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1730430 Kiniksa Pharmaceuticals Ltd. KNSA () DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1583977 Cormorant Asset Management, Lp 200 Clarendon Street, 52Nd Floor
Boston MA 02116
No No Yes No
1599214 Bihua Chen C/o Cormorant Asset Management, Llc
100 High Street, Suite 1103
Boston MA 02110
Yes No Yes No
1618442 Cormorant Global Healthcare Master Fund, Lp 100 High Street
Suite 1105
Boston DC 02110
No No Yes No
1618451 Cormorant Global Healthcare Gp, Llc 100 High Street
1 Federal Street
Boston MA 02110
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Class A Common Shares ("common Shares") Acquisiton 2018-05-29 830,999 $0.00 830,999 No 4 C Indirect See Footnote
Common Shares Acquisiton 2018-05-29 69,444 $18.00 900,443 No 4 P Indirect See Footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See Footnote
No 4 P Indirect See Footnotes
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Shares Series C Preferred Shares Disposition 2018-05-29 830,999 $0.00 830,999 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Direct
Footnotes
  1. The Series C Preferred Shares were convertible at any time, at the holder's election, on a 1-for-2.73235 basis and had no expiration date but converted automatically upon the closing of the Issuer's initial public offering.
  2. Shares reported herein are held by Cormorant Private Healthcare Fund I, LP (the "Fund I"), Cormorant Global Healthcare Master Fund, LP (the "Master Fund") and by a managed account (the "Account"). Cormorant Asset Management, LLC ("Cormorant") serves as the investment manager of Fund I, the Master Fund and the Account. Bihua Chen serves as manager of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.
  3. Shares reported herein represent (i) 640,617 Common Shares held by Fund I, (ii) 161,962 Common Shares held by the Master Fund, and (iii) 28,420 Common Shares held by the Account.
  4. Shares reported as purchased herein on May 29, 2018 represents (i) 60,291 shares purchased by the Master Fund, and (ii) 9,153 shares purchased by the Account.